Sophora alopecuroides biflavones glycoside, isolated from Sophora alopecuroides, inhibits the secretion of hepatitis B virus surface antigen through direct interaction with its antigenic loop domain

从苦参(Sophora alopecuroides)中分离得到的苦参双黄酮糖苷,可通过与乙型肝炎病毒表面抗原的抗原环结构域直接相互作用,抑制乙型肝炎病毒表面抗原的分泌。

阅读:1

Abstract

BACKGROUND: High levels of circulating hepatitis B surface antigen (HBsAg) contribute to the dysfunction of the host immune response against HBV and the persistence of viral infection. This study aimed to investigate the effects and mechanisms of Sophora alopecuroides biflavones glycoside (SABG), isolated from the traditional herbal medicine Sophora alopecuroides, on HBV replication and HBsAg secretion. METHODS: To systematically evaluate the antiviral efficacy, a comprehensive set of experimental analyses was employed, including qPCR, RT-qPCR, ELISA, Western blot and particle gel assay. The DIA-based proteomic analysis, CETSA, molecular docking, and molecular dynamics simulation analyses were combined to explore the potential mechanisms. RESULTS: We discovered that SABG could not only remarkably inhibit intracellular level of HBV core DNA but also significantly reduce the extracellular levels of HBV DNA, pgRNA, HBsAg and e antigen (HBeAg). Intriguingly, SABG had no impact on the intracellular levels of HBV pgRNA and core protein; instead, it caused abnormal accumulation of S protein. Further mechanistic studies revealed that SABG could bind directly to the antigenic loop (AGL) domain of HBs, thereby obstructing its post-translational cellular vesicle-based transport process. Finally, we observed a synergistic effect of SABG and lamivudine in the inhibition of intracellular level of HBV core DNA and the extracellular level of HBsAg. CONCLUSION: Our studies reveal that SABG exhibits an antiviral activity against HBV by directly binding to the antigenic loop of surface protein, thereby impeding its secretion, which provides pharmacological evidence for the potential use of SABG as a candidate for the alternative treatment of HBV infection.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。